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Background: Five diseases are currently screened on dried blood spots in France through the national newborn
screening programme. Tandem mass spectrometry (MS/MS) is a technology that is increasingly used to screen newborns
for an increasing number of hereditary metabolic diseases. Medium chain acyl-CoA dehydrogenase deficiency (MCADD)
is among these diseases. We sought to evaluate the cost-effectiveness of introducing MCADD screening in France.
Methods: We developed a decision model to evaluate, from a societal perspective and a lifetime horizon, the
cost-effectiveness of expanding the French newborn screening programme to include MCADD. Published and, where
available, routine data sources were used. Both costs and health consequences were discounted at an annual rate of 4%.
The model was applied to a French birth cohort. One-way sensitivity analyses and worst-case scenario simulation were
performed.
Results: We estimate that MCADD newborn screening in France would prevent each year five deaths and the
occurrence of neurological sequelae in two children under 5 years, resulting in a gain of 128 life years or 138 quality-
adjusted life years (QALY). The incremental cost per year is estimated at €2.5 million, down to €1 million if this expansion
is combined with a replacement of the technology currently used for phenylketonuria screening by MS/MS. The resulting
incremental cost-effectiveness ratio (ICER) is estimated at €7 580/QALY. Sensitivity analyses indicate that while the results
are robust to variations in the parameters, the model is most sensitive to the cost of neurological sequelae, MCADD
prevalence, screening effectiveness and screening test cost. The worst-case scenario suggests an ICER of €72 000/QALY
gained.
Conclusions: Although France has not defined any threshold for judging whether the implementation of a health
intervention is an efficient allocation of public resources, we conclude that the expansion of the French newborn
screening programme to MCADD would appear to be cost-effective. The results of this analysis have been used to
produce recommendations for the introduction of universal newborn screening for MCADD in France.
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Medium chain acyl-CoA dehydrogenase deficiency
(MCADD) is a hereditary metabolic disease characterised
by decreased ability of the body to use fat as a source of
energy during periods of fasting or increased metabolic
need. It is due to a deficit of the medium chain acyl-CoA* Correspondence: f.hamers@has-sante.fr
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distribution, and reproduction in any mediumdehydrogenase enzyme and is transmitted through an
autosomal recessive mode. Affected individuals may
present with hypoketotic hypoglycaemia, which may lead
to coma or death. If individuals are detected before a life-
threatening episode, the complications of MCADD are,
however, preventable by avoiding fasting stress and pro-
viding regular feeds in the first years of life.
The prevalence of MCADD at birth among Caucasian
populations ranges between 1/10 000 and 1/27 000 [1-8].
In France, while epidemiological studies of a sufficientBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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likely that the prevalence lies within the range of the ex-
treme values found in the neighbouring countries.
Universal newborn screening based on a dried blood
spot test is a well-established, government-funded
programme in France. It is currently organised through a
network of 22 regional labs and its coverage is over
99.99%. It includes five diseases – phenylketonuria (PKU),
congenital hypothyroidism, congenital adrenal hyperplasia,
cystic fibrosis, and, among high-risk populations, sickle
cell disease.
The development of tandem mass spectrometry (MS/
MS) in the early 1990s led to a substantial increase in
the number of potentially detectable hereditary meta-
bolic diseases. This technology is being used to screen
newborns for an increasing number of diseases in an in-
creasing number of countries in Europe [9] and
elsewhere.
The French National Authority for Health (HAS)
was asked by the Ministry of Health to evaluate
options and to produce public health recommendations
concerning the expansion of the national newborn
screening programme for inborn errors of metabolisms
using MS/MS. Based on a preliminary literature
review, it was agreed to start by evaluating the expan-
sion of newborn screening to MCADD, a disease for
which there is ample evidence to suggest that newborn
screening is an effective and cost-effective intervention
[10-22]. Cost-effectiveness was considered by the
French health authorities to be an important element
to inform policy decision even though France has not
defined any incremental cost-effectiveness ratio (ICER)
threshold for the implementation of new public health
interventions.
Several economic analyses of MCADD newborn
screening have been performed in Europe [10,13-15] and
North America [18-23], and several reviews of such eco-
nomic analyses have been published [10,13,24,25]. Esti-
mates of cost-effectiveness of MCADD screening varied
widely, depending on the modelling assumptions [25].
One Canadian study estimated an ICER of 253 161
Canadian dollars (about €200 000) per life year (LY)
[22], assuming systematic lifetime supplementation of
carnitine. If, however, it was assumed that supplements
were provided up to the age of 5 years only, MCADD
screening became cost-saving. In another Canadian
study [21], where no carnitine supplementation was
assumed, the ICER was estimated to be 2 676 Canadian
dollars (about €2 000) per quality-adjusted life year
(QALY). As highlighted in a recent review, more data
are needed to reduce the uncertainty surrounding a
number of parameters, particularly the proportion of
MCADD cases who die in the first few days of life and
will thus never be detected by screening, theeffectiveness of screening in preventing MCADD deaths,
the quality of life attached to the different health states,
and the costs of diagnosis and treatment in the absence
of screening [25]. Because of health system specificities
and limitations in transposing health care costs from
one country to another, it was felt important to carry
out a cost-effectiveness analysis of MCADD newborn
screening, taking into account the French setting and,
where available, using local data.Methods
Model structure, data sources and sensitivity analyses
We developed a decision model to evaluate the cost-
effectiveness of the expansion of newborn screening
for MCADD in France. We used the decision analysis
software TreeAge Pro 2009 Healthcare (TreeAge Soft-
ware Inc, Williamstown, MA, USA). The model was
structured according to the economic evaluation
methodological choices defined by HAS [26]. We used
a societal perspective and a lifetime analytic time
horizon, expressed the health consequences in QALY,
and used an annual discounting rate of 4% for both
costs and health effects.
Because PKU, but not the other conditions currently
screened for in France, can be detected by MS/MS, the
expansion of newborn screening to MCADD was evalu-
ated alongside a concurrent switch in the technology
used for PKU screening, from the current fluorometric
method, to MS/MS. The economic modelling was per-
formed in two steps.
In the first step, we evaluated the consequences of
expanding the existing newborn screening program to
include MCADD screening (Figure 1), which implies
the introduction of the MS/MS technology. Second,
we evaluated the consequences of replacing the fluoro-
metric method currently used for PKU with MS/MS.
In this second step, we assumed, conservatively, that
the performances of the PKU screening test were iden-
tical for both technologies, which implies that the
health outcomes were also identical, regardless of the
screening technology used. As the cost of MS/MS
screening remains virtually unchanged irrespective of
the number of conditions being screened, the conse-
quences of this second step only pertain to the incre-
mental cost of the MS/MS screening test over and
above the cost (no longer incurred) of performing
fluorometry for PKU.
Health effects were expressed in LY and in QALY
gained. We calculated, for a French birth cohort (821 000
live births), the incremental cost/saving of screening
and early identification of MCADD (step 1) and of using
MS/MS for PKU screening (step 2); the incremental
health effect in terms of additional LY gained and
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€ per LY and per QALY gained.ICER ¼ Incremental cost=saving MCADD screening  cost PKU fluorometry test
QALY or LYð Þ gainedParameter values were based on published and routine
data sources, where available; otherwise, expert judg-
ment was used (Table 1). Systematic reviews of the lit-
erature were conducted using various electronic
searches (MEDLINE, EMBASE), government reports,
and hand searching journals and reference lists on
the following topics: MCADD screening tests, diagno-
sis, outcome, treatment, effectiveness, cost, and cost-
effectiveness. We used French administrative databases
to estimate costs of MCADD sequelae. We used the na-
tional health insurance 2010 official rate for specialized
medical consultation (€ 23 per consultation). Costs of
MCADD tests were estimated based on 2010 commer-
cial prices of equipment and reagents, and salaries, in
consultation with the national screening programme.
Details on the search strategies and on the values andFigure 1 Decision tree: Expansion of newborn screening to include M
decision node, circles chance nodes, and triangles terminal nodes. The bra
MCADD screening” which is the current situation. Probabilities, costs, and Q
described in Table 1. To evaluate the concurrent cost-effectiveness of switc
to screen for PKU was subtracted from the cost of the MCADD screening tplausible ranges for the model’s parameters and the cal-
culations performed are available (in French) at http://www.has-sante.fr/portail/upload/docs/application/pdf/
2011-07/argu_depistage_neonatal_vf.pdf [27].
One-way sensitivity analyses were conducted on most
parameters, which were varied over a range of plaus-
ible values to estimate the impact of uncertainty in the
data and the robustness of results. A worst-case sce-
nario, where all the parameters that were varied in the
one-way sensitivity analyses were set at their most un-
favourable values, was also simulated. We also con-
ducted sensitivity analyses on the discount rate for the
following values: 0%, 3%, and 6%.
Probabilities
MCADD prevalence
In the absence of any relevant epidemiological study, the
prevalence of MCADD in France was assumed to beCADD vs. current newborn screening. The square represents a
nch of the decision node “MCADD screening” is compared to “No
ALY are calculated at each terminal node according to the parameters
hing to MS/MS for PKU screening, the cost of the current technology
est as described in the text.
Table 1 Value of the parameters used in the MCADD newborn screening cost-effectiveness analysis model
Parameter Base-case value Range for sensitivity
analyses
References
MCADD birth prevalence 1/15 000 1/10 000–1/25 000 Expert judgement*
Performances of MCADD screening test
Sensitivity 1 [28]
Specificity 0.9998 0.9997 – 1 [2,4,29-36]
Probability of MCADD complications
Death≤ 72 hours of life 0.02 0.02 – 0.05† Expert judgement*
Metabolic crisis 0.67 0.67 – 0.75 [37]
Death after a metabolic crisis 0.20 0.10 – 0.30 {[17,38-44]
Severe sequelae} 0.05 0 – 0.05 [38-41,43-45]
Mild sequelae} 0.05 0 – 0.05 [38-41,43-45]
Effectiveness of screening to prevent metabolic crisis 0.75 0.50 – 0.75 [17]
Life expectancy (years)
Normal 81 French census
Death after metabolic crisis 1.2 [46]
Severe sequelae 56 [47] See text
Mild sequelae 70 [47] See text
Heath-related quality of life
Not affected by MCADD 1 0.90 – 1 See text
Mild sequelae 0.89 0.89 – 0.92 [14]
Severe sequelae 0.76 0.50 – 0.76 [14]
Costs of screening test
Screening test (€) (tests/lab/year)** 3.75 (50 000) 3.38 – 5.16 (60 000 – 30 000) See text
Confirmatory test (€) 500 See text
Cost of treatment of uncomplicated MCADD and MCADD sequelae
L-carnitine (€)†† 6 065 0 – 12 130 See text
Medical consultations (€){{ 888 888 – 1 264 See text
Metabolic crisis (€) 2 770 2 770 – 4 730 Database
Severe sequelae}} 21 000 15 000 – 150 000 Database
Mild sequelae}} 6 000 4 500 – 120 000 Database
*Expert judgment based on available literature, see text.
† Mortality within 24 hours of life is susceptible to be lower in the presence (2%) than in the absence (5%) of a screening programme because of better
knowledge and awareness of the disease by clinicians.
{ Point estimate produced by pooling available literature data.
} Neurological sequelae after a metabolic crisis.
** The unit cost of the screening test depends on the annual number of tests per lab (shown in parentheses).
†† Cost of supplement in L-carnitine until the age of 18 shown, discounted. The proportion of patients treated is 50% in the base-case, ranging from 0% to 100%
in the alternative scenarios.
{{ Cost of medical consultations discounted during the duration of life. The number of medical consultations per year in the absence of complication is two in
the base-case analysis and five until the age of 6 then two during the remaining life in the alternative scenario.
}} Annual cost includes special education and residential care. Lifetime costs were computed based on estimated life expectancies, see text.
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bouring countries. A value of 1 in 15 000 live births was
assumed, with a range of plausible values between 1 in
10 000 and 1 in 25 000 [1-8].
Screening test performance
MS/MS is the only available method to screen for
MCADD. Its specificity, which has been evaluated in a
number of studies, ranges from 99.97% to 100% [2,4,29-36].We used a median value of 99.98%. Its sensitivity is consid-
ered to be 100% [28].
The current method used in France to screen for PKU
is fluorometry. Its specificity has been estimated to be
99.97% and its sensitivity to be 99.3% [48]. Compared to
fluorometry, MS/MS appears to have a greater specificity
and sensitivity [49-51]. We made the conservative as-
sumption that these measures were identical for the two
methods.
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The probability of dying within 24 hours of life, i.e. be-
fore screening could be performed or its results be avail-
able, was estimated at 2%. This estimate was based on
the results from an Australian study where the propor-
tion of deaths before 24 hours was 2% (1/41) among
screened children and 8% (3/30) among unscreened
children [52] and from a study in New England where
no early neonatal death was observed among 47 chil-
dren detected with MCADD by screening [35].
In the absence of screening, two thirds to three
quarters of individuals with MCADD will develop a
metabolic crisis [17,37]. We used a conservative value
of two-thirds (67%) for this parameter. The risk of
death following a metabolic crisis was estimated at
20% by pooling data from available studies [17,38-44].
Based on available literature, the probability of devel-
oping severe and the probability of developing mild
neurological complications after a metabolic crisis were
both estimated to be 5% [38-41,43-45].
Effectiveness of MCADD screening
In a large Australian cohort study on MCADD screen-
ing [17], the cumulative relative risk of death or severe
metabolic decompensation by age 2 years was esti-
mated to be 0.26 (which would correspond to an ef-
fectiveness to prevent adverse outcomes of 74%), with
more liberal and more conservative estimates of 0.19
and 0.44, respectively. On this basis, the effectiveness
of MCADD screening to prevent a metabolic crisis was
assumed to be 75% with a plausible lower-bound at
50%.
Life expectancies
We assumed that the life expectancy (LE) at birth of a
child with MCADD who will not develop neurological
sequelae (or otherwise die from MCADD) is the same as
that of an average person, i.e. 81 years (the mean be-
tween male and female LE in France in 2009) [53]. The
LE of a child who will die from an MCADD metabolic
crisis was assumed to be 1.2 years [46]. Likewise, the age
at which a metabolic crisis occurs was assumed to be
1.2 years.
No data on LE of patients with MCADD and neuro-
logical sequelae were identified. Estimates were there-
fore derived from a population-based study using data
from the state of California [47], which calculated a LE
of 65 years for children with mild or moderate mental
retardation who did not have Down syndrome, and of
51 years for those with severe mental retardation. These
figures correspond to reductions of 11 years and
25 years respectively with respect to the average LE of
76 years in the 1992 US life tables used in the Califor-
nian study. For the purpose of our model, wesubtracted these same figures from the current French
LE of 81 years, giving estimated LE of 70 and 56 years,
which we used for mild and for severe neurological se-
quelae, respectively.Health-related qualities of life
Quality of life was estimated by a utility score ranging
from 0 (death) to 1 (perfect health). We assumed that
the utility score of persons with MCADD who did not
develop neurological sequelae was the same as that of
persons without MCADD and that it was equal to 1. We
used a value of 0.9 in the sensitivity analysis to take into
account the fact that these persons may suffer from
other types of disease or impairment.
We did not reduce the utility score in case of a false-
positive screening result, which is defined as an abnor-
mal screening test followed by a repeat screening test or
further investigation that does not indicate an MCADD
diagnosis. Indeed, a US study suggests that parents have
a high tolerance to false positive newborn screening
results [54] and the incorporation of the loss in quality
of life associated with false positive test results did not
noticeably increase the ICER [23].
For the quality of life related to neurological sequelae,
only one study, conducted in Finland and based on a
multi-attribute utility instrument, estimated utility scores
for neurological sequelae due to MCADD, which were
0.89 and 0.76 for mild and severe neurological sequelae,
respectively [14].Costs
Cost of screening test and of diagnostic test
The collection and transportation of dried blood spots
are part of the current newborn screening programme.
Therefore these costs could be excluded from the cost-
effectiveness analysis. Furthermore, any potential
changes in the lab location (see below) would have no
impact on transportation costs as dried blood spots are
sent by post with charges that are uniform across
France.
Therefore, the cost of the MCADD screening test
used in the model was limited to lab costs including
capital equipment, consumables and personnel. Costs of
equipment, including maintenance and consumables,
were provided by screening lab experts and also
obtained from suppliers. Personnel inputs required to
operate MS/MS in a newborn screening lab were esti-
mated in consultation with the national newborn
screening programme. The cost of a MS/MS machine
represents a high initial capital spending. It constitutes a
fixed cost regardless of the number of specimens
screened, at least for a large range of number of speci-
mens up to the maximum capacity of the machine.
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reduction in the number of labs that are performing
newborn screening tests, in order to guarantee the qual-
ity of the technical expertise and to achieve efficiency.
On the basis of 50 000 specimens tested per machine
per year and a machine lifespan of 5 years, and using
a 4% annual discount rate, the cost of MCADD
screening was estimated to be €3.75 per test. The
estimated cost of the screening test decreased at a de-
creasing rate with the number of specimens tested
per machine (and hence per lab, assuming one ma-
chine per lab) per year, from €5.85 for 25 000 speci-
mens to €2.67 for 100 000 specimens per machine
per year.
The cost of the diagnostic test to confirm a positive
screening test depends on the screening algorithm used.
It was estimated in consultation with the national
screening programme to be €500, which includes the
costs of contacting the child, of a medical consultation
and of additional lab tests. It was assumed, conserva-
tively, that both the cost of further investigation in case
of a false positive screening test result and the cost of
diagnosing a case of MCADD, in the absence of screen-
ing, would also be €500.
Based on the fee paid by the national health insurance
scheme to the screening labs [55], the cost of the exist-
ing technology for PKU screening (fluorometry) was
estimated at €1.76 per test.
Cost of uncomplicated MCADD
The management of uncomplicated MCADD consists
in dietary management to preventing fasting stress. It
was assumed, based on expert opinion, that persons
diagnosed with MCADD have on average two medical
consultations (at €23 each) per year until the age of
6 years, then one consultation per year for the rest of
their life. In a sensitivity analysis, the number of med-
ical consultations was varied from two to five per year
during the first 6 years of life. Regarding L-carnitine
supplementation, there is no good quality study nor ex-
pert consensus on its effectiveness [10,56], data on pre-
scription habits in France are lacking, and its use in
other countries is heterogeneous. Therefore, in the
base-case analysis, it was assumed that 50% of children
diagnosed with MCAD receive a supplementation in
L-carnitine until the age of 18 years, after which the
supplementation is stopped. Two alternative scenarios
were evaluated in the sensitivity analysis where, respect-
ively, no children and all diagnosed children receive
L-carnitine until the age of 18 years. Costs were esti-
mated on the basis of the recommended posology and
mean weights for age according to French growth charts.
In the reference scenario, the discounted cost, for a
population LE of 81 years, was estimated at €5 831 (€888for the medical consultations plus €4 942 for L-carnitine
supplementation).
Cost of MCADD complications and sequelae
The cost of a metabolic crisis was estimated using the
hospital administrative database “Programme de méd-
icalisation des systèmes d’information” (PMSI) by com-
puting the weighted average fee of the disease related
groups corresponding to the International Classification
of Disease (ICD) 10 code “disorders of fatty-acid metab-
olism”. The cost amounted to €2 770.
There are no specific data available on the costs of
managing neurological sequelae of metabolic diseases
in France. Using a French claim database (“Echantillon
généraliste des bénéficiaires”), we analysed the annual
management cost for patients with long-term illnesses
diagnosed with mental retardation (ICD-10: F70–79), as
a proxy for severe MCADD neurological sequelae, and
for patients with behavioural and emotional disorders
with onset in childhood and adolescence (ICD-10:
F90–98) as proxy for mild sequelae. These costs, which
are covered by the national health insurance scheme,
include health care costs as well as other expenses such
as special education, residential care, and transporta-
tion. They were highly variable, with a median of €21
352 (99% confidence interval [CI]: €17 074–€25 540)
and a mean of €125 106 (99% CI: €101 450–€148 171)
for mental retardation and a median of €6 306 (99%
CI: €4 822–€8 703) and a mean of €77 581 (99% CI:
€46 910–€118 558) for behavioural and emotional dis-
orders. We used the median costs in the base-case ana-
lysis and the lower bound of the median and upper
bound of the mean as extreme values in the sensitivity
analysis. We computed lifetime discounted costs based
on the estimated LE for neurological sequelae.
Results
Base-case analysis
The model projected that the introduction of MCADD
screening into the French newborn screening
programme would, every year, prevent five child deaths
and the occurrence of severe neurological sequelae in
one child and mild neurological sequelae in one other
child under five years, which results in a gain of 128 LY
or 138 QALY (Table 2). The cost of the tests (including
screening and confirmation tests) was estimated at €3.2
million. When the costs of treatment and care were
taken into account, the net incremental cost of introdu-
cing MCADD screening was lower – estimated at €2.5
million – because of the MCADD complications
prevented. The resulting ICER was €19 478 per LY or
€18 033 per QALY gained.
When the introduction of MCADD screening was
combined with a switch in technology for PKU
Table 2 Cost-effectiveness of the introduction of MCADD newborn screening in France
Description of results Introduction of
MCADD screening
Introduction of MCADD screening
combined with switch to MS/MS for PKU
screening*
Effectiveness
Deaths averted 5.47 5.47
Mild neurological sequelae prevented 1.37 1.37
Severe neurological sequelae prevented 1.37 1.37
LY gained 128 128
QALY gained 138 138
Costs
Costs of testing alone† (€) 3 187 660 1 742 702
Net incremental costs of screening {(€) 2 493 055 1 048 097
Incremental cost-effectiveness ratios
€ per LY gained 19 478 8 189
€ per QALY gained 18 033 7 581
* The cost of the current technology PKU screening test (€1.76) was subtracted from that of the MS/MS screening test. The incremental effectiveness was the
same as that for the introduction of MCADD screening alone as it was assumed that the performance of MS/MS for PKU screening was similar to that of the
current technology; see text.
† Includes the cost of screening and confirmation tests.
{ Includes the cost of testing as well as the cost of follow-up and of management of diagnosed patients.
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remained the same as in the above strategy because the
performances of MS/MS and of fluorometry for PKU
screening were assumed to be similar. However, the in-
cremental cost of the screening programme was lower
because of the savings from no longer having to per-
form the current PKU test. The annual cost of the tests
was estimated at €1.7 million and the annual net incre-
mental cost of the screening programme at €1.0 mil-
lion. The resulting ICER was estimated at €8 189 per
LY or €7 851 per QALY gained. As expected, this strat-
egy clearly dominated that of solely introducing
MCADD screening.
Sensitivity analyses
One-way sensitivity analyses showed the influence of
variations, within plausible ranges, of different para-
meters on the results of the model (Table 3 and
Figure 2). The parameters that had the largest influ-
ence include the costs of neurological sequelae, for
which estimates were highly uncertain; the MCADD
prevalence; the cost of the MCADD screening test,
which is dependent on the number of tests per lab per
year and ultimately on the number of labs performing
screening tests; the risk of death following a metabolic
crisis; and the effectiveness of MCADD screening. For
example, the ICER varied from €3 444 to €15 856 per
QALY gained when the MCADD prevalence varied
from 1/1000 to 1/25 000. Likewise, the ICER rose to
€15 655 per QALY if the cost per test was increased
to €5.16 (which would correspond to 30 000 tests perlab per year). When the annual costs of managing
neurological sequelae exceeded €50 000 for severe se-
quelae or €40 000 for mild sequelae, the programme
became cost-saving.
The worst-case scenario indicated that the ICER
of introducing MCADD screening and of switching to
MS/MS for PKU screening would be, at worst, equal to
€72 115 per QALY gained.
Discussion
The objective of this cost-effectiveness analysis was to
inform policy makers and help them decide whether or
not to introduce MCADD screening in France.
The predicted ICER of MCADD screening in France
– €7 580 per QALY gained – is within the range of
those obtained by others [10,13-15,18-23]. While there
is no defined threshold in France for judging whether
the implementation of a health intervention is an effi-
cient allocation of public resources, this analysis sug-
gests, in view of efficiency thresholds defined in other
European countries, that the introduction of MCADD
screening in France is cost-effective. In England, inter-
ventions with an ICER of less than £20 000 to
£30 000 (around €24 000 to €36 000) per QALY
gained are considered to be cost-effective [57]. In Swe-
den, the threshold to decide whether a drug provides
value for money and to determine coverage status is
€45 000 per QALY [58] and in the Netherlands, this
threshold may be as high as €80 000 per QALY for
severe conditions [59]. The World Health Organisation
considers that health intervention are very cost-effective
Table 3 One-way sensitivity analyses of the cost-effectiveness of introducing MCADD screening and of switching to
MS/MS technology for PKU screening
Parameter Value or range for
sensitivity analyses
ICER (€/QALY)
Base-case values 7 581
MCADD birth prevalence 1/10 000 to 1/25 000 3 444 to 15 856
MCADD screening test specificity 0.9997 to 1 7 878 to 6 987
Risk of developing a metabolic crisis 0.75 5 881
Risk of death within 72 hours of life 0.05 5 902
Risk of death after a metabolic crisis 0.01 to 0.03 13 180 to 5 314
Risk of mild neurological sequelae 0 9 175
Risk of severe neurological sequelae 0 12 823
Screening effectiveness (reduction in the risk of developing a metabolic crisis) 0.5 14 351
Utility of persons unaffected by MCADD 0.9 8 769
Utility of persons with severe neurological sequelae 0.45 7 121
Utility of persons with mild neurological sequelae 0.92 7 632
Cost of the MCADD screening test (€) 3.38 to 5.16 5 384 to 15 655
Annual cost of management of severe 15 000 to 150 000 8 832 to −19 139*
Annual cost of management of mild neurological sequelae (€) 4 500 to 120 000 7 911 to −17 353*
Cost of treatment of a metabolic crisis 4 730 7 211
% patients receiving L-carnitine supplementation until 18 years of age 0% to 100% 6 617 to 8 546
Number of medical consultations per year until 6 years of age 5 7 667
No discounting −514*
Annual discounting rate 3% to 6% 4 954 to 13 598
* A negative cost-effectiveness ratio indicates that the strategy is both more effective and less costly than the comparison strategy.
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tic product (GDP) per disability adjusted life year averted
(DALY) for a given country or region. Interventions that
costs up to three times the average per capita GDP per
DALY averted are still considered cost-effective, while
those that exceed this threshold are considered not cost-
effective [60]. For France, these thresholds would corres-
pond to about €30 000 and €90 000 per DALY averted,
respectively.Figure 2 Sensitivity analyses: Expansion of newborn screening to incl
indicates the variation in the incremental cost-effectiveness ratio associated
right side, next to the parameters, indicate the lower- and upper-bounds oThe results of the model were relatively robust to the
variations of parameters applied in the one-way sensitiv-
ity analyses, whereby the ICER remains below €16 000
per QALY gained. The model was, however, more sensi-
tive to some parameters, some of which are subject to a
large degree of variability (notably the cost of neuro-
logical sequelae) or uncertainty (e.g. MCADD preva-
lence, cost of MCADD screening test). The production
of empirical data generated by the implementation ofude MCADD vs. current newborn screening. The width of the bar
with alternative parameter values for that input. The numbers on the
f the ranges used in sensitivity analyses.
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The costs used in this analysis did not include the
start-up costs for launching the programme, such as the
costs of staff training and of producing information and
education materials. While the use of MS/MS technol-
ogy for newborn screening implies that the number of
labs performing screening tests be reduced, the intan-
gible costs related to potential disruption of the current
newborn screening programme incurred by such reorga-
nisation have not been taken into account either. We
did not incorporate the potential loss of quality of life
associated with lifelong dietary recommendations for
treating MCADD in patients who may in the absence of
screening not have experienced any MCADD related
problems. Yet, such adjustments may counterbalance
some of the health gains from newborn screening [23].
The budget impact for the national health insurance
scheme of the expansion of the newborn screening
programme to MCADD and of the replacement of exist-
ing technology for PKU screening was estimated at €1.7
million per year for the tests alone and at €1 million
when the savings from preventing MCADD sequelae
were taken into account. This amount represents an in-
crease of 11% in the annual cost (currently estimated at
€9 million) of the newborn screening programme.
Conclusions
This analysis suggests that implementing MCADD new-
born screening in France would be an efficient use of
resources. These results were used by HAS as support-
ing evidence to recommend the expansion of newborn
screening to include MCADD. The French Ministry of
Health is currently making plans to put these public
health recommendations into practice.
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